
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences is poised for significant growth, with expectations of Cologuard, its flagship colorectal cancer screening test, achieving an increase in market share from approximately 15% to a long-term goal of over 40%. The company reported a remarkable 22% year-over-year growth in its core screening business during Q3 2025 and raised its 2025 revenue guidance, reflecting strong demand and higher average selling prices for Cologuard Plus. Additionally, the launch of the Cancerguard blood test, targeting over 50 cancer types, is anticipated to contribute incrementally to sales and marketing efforts, further enhancing the company's financial trajectory.
Bears say
The analysis indicates that Exact Sciences is facing challenges in sustaining profitability, as evidenced by its history of net losses and uncertainty regarding the achievement of GAAP profitability. Additionally, the demand for its Cologuard test is highly dependent on marketing spending, suggesting that the company's revenue may be vulnerable to fluctuations in promotional activities. Furthermore, revenue estimates for 2027 fall short of targets, raising concerns about growth potential despite potential benefits from new licensing agreements and expected increases in demand for its diagnostic products.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares